Antiproliferative effect of ascorbic acid is associated with the inhibition of genes necessary to cell cycle progression

PLoS ONE

Volumn 4, Issue 2, 2009, Pages

  Belin, Sophie ^a   Kaya, Ferdinand ^a   Duisit, Ghislaine ^a   Giacometti, Sarah ^a   Ciccolini, Joseph ^a   Fontés, Michel ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID TRANSFER RNA LIGASE; ASCORBIC ACID; CYCLIC AMP; INITIATION FACTOR; PLACEBO;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL DEATH; CELL PROLIFERATION; CELL STRAIN HT29; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; GENE EXPRESSION REGULATION; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; NUDE MOUSE; PROTEIN SYNTHESIS INHIBITION; TUMOR VOLUME;

ANIMALIA; MUS MUSCULUS;

EID: 84860475014     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0004409     Document Type: Article

References (25)

1. Passage E, Norreel JC, Noack-Fraissignes P, Sanguedolce V, Pizant J, et al. (2004) Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat Med 10: 396-401.
2. Kaya F, Belin S, Bourgeois P, Micaleff J, Blin O, et al. (2007) Ascorbic acid inhibits PMP22 expression by reducing cAMP levels. Neuromuscul Disord 17: 248-253.
3. Kaya F, Belin S, Micallef J, Blin O, Fontes M (2008) Analysis of the benefits of vitamin cocktails in treating Charcot-Marie-Tooth disease type 1A. Muscle Nerve 38: 1052-1054.
4. Kaya F, Belin S, Diamantidis G, Fontes M (2008) Ascorbic acid is a regulator of the intracellular cAMP concentration: Old molecule, new functions? FEBS Lett.
5. Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3: 1101-1108.
6. Enger MD, Ritter PO, Hampel AE (1978) Altered aminoacyl-tRNA synthetase complexes in G1-arrested Chinese hamster ovary cells. Biochemistry 17: 2435-2438.
7. Hohmann S, Thevelein JM (1992) The cell division cycle gene CDC60 encodes cytosolic leucyl-tRNA synthetase in Saccharomyces cerevisiae. Gene 120: 43-49.
8. Mazeyrat S, Saut N, Grigoriev V, Mahadevaiah SK, Ojarikre OA, et al. (2001) A Y-encoded subunit of the translation initiation factor Eif2 is essential for mouse spermatogenesis. Nat Genet 29: 49-53.
9. Pollard JW, Stanners CP (1979) Characterization of cell lines showing growth control isolated from both the wild type and a leucyl-tRNA synthetase mutant of Chinese hamster ovary cells. J Cell Physiol 98: 571-585.
10. Suss J, Mach H, Mach F (1972) [Aminoacyl-t RNA-synthetases and cell division in a temperature sensitive filiform mutant of Bacillus subtilis SB 19]. Z Allg Mikrobiol 12: 161-168.
11. Motomura S, Fukushima K, Nishitani H, Nawata H, Nishimoto T (1996) A hamster temperature-sensitive G1 mutant, tsBN250 has a single point mutation in histidyl-tRNA synthetase that inhibits an accumulation of cyclin D1. Genes Cells 1: 1101-1112.
12. Pauling L, Moertel C (1986) A proposition: megadoses of vitamin C are valuable in the treatment of cancer. Nutr Rev 44: 28-32.
13. Chen Q, Espey MG, Krishna MC, Mitchell JB, Corpe CP, et al. (2005) Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci U S A 102: 13604-13609.
14. Chen Q, Espey MG, Sun AY, Lee JH, Krishna MC, et al. (2007) Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad Sci U S A 104: 8749-8754.
15. Heckelen A, Hermel M, Kondring B, Schrage NF (2004) Ascorbic acid reversibly inhibits proliferation of retinal pigment epithelial cells. Acta Ophthalmol Scand 82: 564-568.
16. Pauling L, Nixon JC, Stitt F, Marcuson R, Dunham WB, et al. (1985) Effect of dietary ascorbic acid on the incidence of spontaneous mammary tumors in RIII mice. Proc Natl Acad Sci U S A 82: 5185-5189.
17. Cameron E, Campbell A (1974) The orthomolecular treatment of cancer. II. Clinical trial of high-dose ascorbic acid supplements in advanced human cancer. Chem Biol Interact 9: 285-315.
18. Moertel CG, Fleming TR, Creagan ET, Rubin J, O'Connell MJ, et al. (1985) High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl J Med 312: 137-141.
19. Assouline S, Miller WH (2006) High-dose vitamin C therapy: renewed hope or false promise? Cmaj 174: 956-957.
20. Kuwai T, Nakamura T, Sasaki T, Kitadai Y, Kim JS, et al. (2008) Targeting the EGFR, VEGFR, and PDGFR on colon cancer cells and stromal cells is required for therapy. Clin Exp Metastasis 25: 477-489.
21. Tremblay PL, Huot J, Auger FA (2008) Mechanisms by which E-selectin regulates diapedesis of colon cancer cells under flow conditions. Cancer Res 68: 5167-5176.
22. Zirvi KA, Dasmahapatra KS, Atabek U, Lyons MA (1989) alpha-Difluoromethylornithine inhibits liver metastasis produced by intrasplenic injection of human tumor cells into nude mice. Clin Exp Metastasis 7: 591-598.
23. Padayatty SJ, Sun H, Wang Y, Riordan HD, Hewitt SM, et al. (2004) Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med 140: 533-537.
24. Chen Q, Espey MG, Sun AY, Pooput C, Kirk KL, et al. (2008) Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci U S A 105: 11105-11109.
25. Hoffer LJ, Levine M, Assouline S, Melnychuk D, Padayatty SJ, et al. (2008) Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Ann Oncol.